ERBB2 and neoplasm: This latter phenomenon is biologically consistent with results reported by Ciravolo et al. and Battke et al. on Trastuzumab-treated breast carcinoma cells [33, 54]: exosomes secreted by HER2-overexpressing breast carcinoma cell lines express HER2 molecule, enabling them to bind to HER2 antibody Trastuzumab both in vitro and in vivo; these exosomes efficiently bound and sequestered tumor-reactive antibodies and dramatically reduced their binding to tumor cells: in this way, they inhibited the overall effect of Trastuzumab on cancer cells proliferation.